<DOC>
	<DOCNO>NCT00793546</DOCNO>
	<brief_summary>This phase 2 , open-label , multicenter , 2-arm study bosutinib administer combination exemestane versus exemestane alone . This 2-part study consist safety lead-in phase randomize phase 2 portion . Subjects part 1 receive bosutinib exemestane daily , closely monitor 28 day . If safety concern arise , future eligible subject randomly assign main phase study . They either receive bosutinib daily combine daily exemestane , daily exemestane alone specified period time . Subjects follow survival treatment discontinuation .</brief_summary>
	<brief_title>Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone Post Menopausal Women With Breast Cancer</brief_title>
	<detailed_description>This study terminate 19 Apr 2010 due unfavorable risk benefit ratio support continuation part 2 study . Even safety profile combination Bosutinib Exemestane acceptable 25 % subject treatment relate liver event include 14 % severe liver event .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Woman age 18 year old . Confirmed pathologic diagnosis breast cancer . Locally advance , metastatic , locoregional recurrent breast cancer amenable curative treatment surgery radiotherapy . Surgically sterile postmenopausal woman . Documented ER+ and/or PgR+ erbB2 tumor . Progression locally advance metastatic disease treatment nonsteroidal AI tamoxifen , progression treatment ( within 6 month discontinuation ) adjuvant nonsteroidal AI . Prior exemestane , prior bosutinib , prior antiSrc therapy . More 1 prior endocrine treatment locally advance MBC . More 1 prior cytotoxic chemotherapy regimen metastatic setting . Bone skin site disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Bosutinib</keyword>
	<keyword>Exemestane</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>breast cancer</keyword>
</DOC>